메인메뉴 바로가기

All Menu

About Us Business & Products R&D new products/R&D Plants & Quality Careers News

Hanmi Fine Chemical.Co.,Ltd.

글로벌메뉴

메인메뉴


HomeR&DResearch Center & Organization

R&D

Research Center & Organization

API Research Center, with basic principles of 'respect for life'

API Research Center contributes to the promotion of public health by manufacturing outstanding products and to the strengthening of national competitiveness through global export, under the basic principle of “respect for life."

In December 1993, a research institute dedicated to independent process improvement and research and development of new products and improvement was launched as Hanmi API Research Center, separately from the Hanmi Pharm Research Center. At present, Hanmi Fine Chemical invests 5 percent of the total annual sales amount toward the R&D efforts of the API Research Center.

The antibiotics market is the arena of competition among the domestic and foreign pharmaceutical companies. Hanmi Fine Chemical has maintained its leadership position in this competitive market due to the competency of the API Research Center, which aims to further contribute to the promotion of public health by manufacturing outstanding products and to the strengthening of national competitiveness through global export, under the basic principle of “respect for life.” The Center is comprised of five teams, with each team striving to become the best in its field and to maintain efficient cooperative ties with one another.

Organization

  • Research Director
    • Research Institute
      • API 1Team
        Patent
      • API 2Team
        New Product/ Patent
      • API 3Team
        New Product/ Patent
      • API 4Team
        New Product/ Patent/CRO,CMO
      • API 5Team
        Patent/Doc/Budget/Education

API Research Center

The Hanmi Fine Chemical API Research Center operates a division to improve the manufacturing processes for the various products such as cephalosporin-based antibiotics (e.g., Cefotaxime, Ceftriaxone, Cefotiam, Ceftazidime, and Cefixime), intermediates (e.g., DACA, 7-ACT, VACA, MACA, PACA, and MAEM), and new, independently-developed AT-derivatives to maintain price and quality competitiveness.

We became the first company in Korea to synthesize a wide range of antibiotics such as oral cephalosporin-based antibiotics (e.g., Cefdinir, Cefuroxime Axetil, and Cefodoxime Proxetil), which is regarded highly for their marketability and efficacy, cephamycin-based antibiotics (e.g., Cefmetazole and Cefotetan) and macrolide-based antibiotics (e.g., Clarithronycin). We are continually developing new products to emerge as the top manufacturer of antiobitics.

Research Management Team

The Hanmi Fine Chemical API Research Center operates a research management team to secure the necessary information such as patent information and perform independent analyses of chemical substances to supplement the accurate and precise synthesis activities with diverse analytical equipment. We are investing into our analytical equipment and apparatuses in recognition of the essentiality of analysis for efficient R&D, new product development and patent challenges. We are also quickly responding to the new trends in the pharmaceutical market and new information available in the field, with an understanding that information and knowledge are directly linked to research power. We select the next-generation products for research and development through careful research planning and operate an R&D project management system.

TOP